NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) were down in after-hours trading on Tuesday after reporting lower-than-expected earnings and sales from hepatitis C treatments for the 2016 third quarter.
After the market close, the Foster City, CA-based biopharmaceutical company reported adjusted earnings of $2.75 per share, missing the FactSet consensus of $2.84 per share.
Revenue of $7.50 billion topped analysts' expectations of $7.46 billion.
Revenue from Gilead's hepatitis C treatments Harvoni and Sovaldi came in at $1.86 billion and $825 million, respectively. Analysts surveyed by FactSet were looking for Harvoni sales of $2.32 billion and Sovaldi sales of $1.06 billion.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Gilead's strenghts such as its notable return on equity, attractive valuation levels and expanding profit margins outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: GILD
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.